A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects

Trial Profile

A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Natalizumab (Primary) ; Fingolimod
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms REVEAL
  • Sponsors Biogen
  • Most Recent Events

    • 08 Jan 2016 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 23 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Mar 2017 to 1 May 2017.
    • 23 Jul 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Mar 2017 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top